The Mayo Clinic is conducting a pilot study of Scibase’s Nevisense.
Nevisense is a point-of-care platform that combines artificial intelligence and advanced Electrical Impedance Spectroscopy (EIS) technology to help dermatologists differentiate challenging benign pigmented lesions from melanomas. EIS uses harmless electrical signals to measure the electrical impedance of the skin at different frequencies.
“Melanoma is the deadliest form of skin cancer and accounts for the majority of skin cancer deaths because it can spread from the skin to other parts of the body where it becomes difficult to treat and can be fatal. However, if caught early, melanoma is almost 100% curable. For these reasons, we are looking forward to understanding how the Nevisense technology can help clinicians in the early detection of melanoma,” says Alexander Meves, MD, MBA, Professor of Dermatology at the Mayo Clinic College of Medicine and Sciences in Rochester, MN, in a news release.
“We are proud to work with the Mayo Clinic and believe this pilot represents an opportunity for SciBase to continue to address an unmet medical need by expanding access of the Nevisense test to more US patients at-point-of-care, when it is critical and makes a profound impact on patient care,” adds Pia Renaudin, CEO of SciBase.
